American Heart Association, 1998 Heart and Stroke Statistical Update. Dallas, Tex American Heart Association1997;
Centers for Disease Control and Prevention, Medical care spending: United States. MMWR Morb Mortal Wkly Rep. 1994;43581- 586
A Health care expenditures for major diseases in 1980. Health Care Financ Rev. 1984;51- 12
et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA.
1993;2693009- 3014Link to Article
R Powerful medications for cholesterol pose a paradox for HMOs. Wall Street Journal December6 1996;A1A11
Jr Medical costs of coronary artery disease in the United States. Am J Cardiol.
1990;65432- 440Link to Article
B The economic impact of stroke. Neurology.
1995;45(suppl 1)S6- S9Link to Article
G Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology.
1996;46854- 860Link to Article
MF Lifetime cost of stroke in the United States. Stroke.
1996;271459- 1466Link to Article
CD Cholesterol reduction yields clinical benefit: a new look at old data. Circulation.
1995;912274- 2282Link to Article
M Efficacy and safety of fluvastatin in women with primary hypercholesterolemia. Drugs.
1994;47(suppl 2)64- 72Link to Article
ESimvastatin Pravastatin European Study Group, Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology.
1994;85244- 254Link to Article
Lovastatin Pravastatin Study Group, A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol.
1993;71810- 815Link to Article
et al. Cholesterol and Recurrent Events Trial Investigators, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med.
1996;3351001- 1009Link to Article
et al. West of Scotland Coronary Prevention Study Group, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med.
1995;3331301- 1307Link to Article
et al. REGRESS Study Group, Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation.
1995;912528- 2540Link to Article
et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med.
1991;15143- 49Link to Article
GSimvastatin and Lovastatin Multicenter Study Participants, Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther. 1992;14708- 717
MEuropean Study Group, Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. Drug Invest.
1993;6353- 361Link to Article
PLEuropean Study Group, Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol. 1993;48541- 554
Not Available, Zocor (simvastatin) [package insert]. West Point, Pa Merck & Co1996;
DCURVES Investigators, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol.
1998;81582- 587Link to Article
et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA.
1996;275128- 133Link to Article
et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol.
1997;7938- 42Link to Article
et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.
1993;119969- 976Link to Article
et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation.
1994;89959- 968Link to Article
Post Coronary Artery Bypass Graft Trial Investigators, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med.
1997;336153- 162Link to Article
et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med.
1990;3231289- 1298Link to Article
MAAS Investigators, Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet.
1994;344633- 638Link to Article
MEPLAC I Investigators, Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol.
1995;261133- 1139Link to Article
PHHarvard Atherosclerosis Reversibility Project (HARP) Group, Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet.
1994;3441182- 1186Link to Article
et al. LCAS Investigators, Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol.
1997;80278- 286Link to Article
et al. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group, Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation.
1994;901679- 1687Link to Article
et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med.
1996;124548- 556Link to Article
et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation.
1995;921758- 1764Link to Article
et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol.
1995;75455- 459Link to Article
et al. AFCAPS/TexCAPS Research Group, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA.
1998;2791615- 1622Link to Article
Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;3441383- 1389
A Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID). Presented at: the American Heart Association Scientific Sessions November 12, 1997 Orlando, Fla
National Cholesterol Education Program, Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;891329- 1445
S Cost of prevention: the case of lipid lowering. Circulation.
1996;931774- 1776Link to Article
DMultiple Risk Factor Intervention Trial Research Group, Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316099 white men. Arch Intern Med.
1992;15256- 64Link to Article
et al. Relationship between plasma LDL concentrations during drug treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation.
1998;971446- 1452Link to Article
West of Scotland Coronary Prevention Study Group, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation.
1998;971440- 1445Link to Article
et al. Scandinavian Simvastatin Survival Study Group, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation.
1998;971453- 1460Link to Article
SM Statin trials and goals of cholesterol-lowering therapy. Circulation.
1998;971436- 1439Link to Article
CD Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med.
1997;1571305- 1310Link to Article
CH Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA.
1997;278313- 321Link to Article
MCPanel on Cost-Effectiveness in Health and Medicine, The role of cost-effectiveness analysis in health and medicine. JAMA.
1996;2761172- 1177Link to Article
R Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics.
1992;120- 32Link to Article
MA Task Force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol.
1996;271020- 1030Link to Article
et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal.
1995;15369- 390Link to Article
LW Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA.
1991;2651145- 1151Link to Article
et al. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease. Am J Cardiol.
1996;78409- 414Link to Article
et al. Scandinavian Simvastatin Survival Study Group, Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation.
1996;931796- 1802Link to Article
HScandinavian Simvastatin Survival Study Group, Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med.
1997;336332- 336Link to Article
SA The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA.
1995;2731032- 1038Link to Article
Jr An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol.
1991;67789- 796Link to Article
R Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994;161052- 1062
DTask Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension, Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;151300- 1331
JN Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet.
1996;348387- 388Link to Article
JN Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Colch). 1996;91399- 413
G Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med.
1994;121641- 647Link to Article
L Serum lipid screening to identify high risk individuals for coronary death: the results of the Lipid Research Clinics prevalence cohort. Arch Intern Med.
1994;154679- 684Link to Article
WB An updated coronary risk profile: a statement for health professionals. Circulation.
1991;83356- 362Link to Article
et al. Coronary Risk and Stroke Prediction Chart and Worksheet. Dallas, Tex American Heart Association1993;
WB Cardiovascular disease risk profiles. Am Heart J.
1991;121293- 298Link to Article
PPCV-METRA Group, Estimation of CHD risk in a French working population using a modified Framingham model. J Clin Epidemiol.
1994;471353- 1364Link to Article
NDyslipidemia Working Group of Health Canada, Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Can J Cardiol. 1998;14(suppl A)17A- 21A
West of Scotland Coronary Prevention Group, West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet.
1996;3481339- 1342Link to Article
Medical Research Council Working Party, MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed).
1985;29197- 104Link to Article
G How well can we predict coronary heart disease? findings in the United Kingdom Heart Disease Prevention Project. Br Med J (Clin Res Ed).
1984;2881409- 1411Link to Article
PM Association of hemostatic and thrombotic factors with cardiovascular risk. Schafer
AIed.Molecular Mechanisms of Hypercoagulable States Austin, Tex Landes Bioscience1997;
et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA.
1994;271999- 1003Link to Article
MJ A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA.
1993;2702195- 2199Link to Article
RB Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA.
1987;2581183- 1186Link to Article
Fvan de Loo
JCWEuropean Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group, Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med.
1995;332635- 641Link to Article
C Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis.
1996;121185- 191Link to Article
AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA.
1995;2741049- 1057Link to Article
GK Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction. Thromb Haemost. 1996;76417- 421
et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med.
1997;336973- 979Link to Article
et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;1391164- 1179
et al. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation.
1996;931951- 1953Link to Article
et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications: a statement for health professionals from the American Heart Association. Circulation.
1996;941175- 1192Link to Article
BH Beyond perfusion with ultrafast computed tomography. Am J Cardiol.
1995;7569D- 73DLink to Article
CJ Ultrafast computed tomography for detection of coronary artery calcification. Am J Card Imaging. 1995;9206- 212
JWOSCOPS Group, The West of Scotland Coronary Prevention Study (WOSCOPS): benefits of pravastatin therapy in compliant subjects [abstract]. Circulation. 1996;94I- 539
E Impact of medication nonadherence on coronary heart disease outcomes. Arch Intern Med.
1997;1571921- 1929Link to Article
W The problem of compliance to cholesterol altering therapy. J Intern Med.
1997;241317- 325Link to Article
IS The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals. Circulation.
1997;951085- 1090Link to Article
TT Lipids and lipoproteins in women. Mayo Clin Proc.
1997;72235- 244Link to Article
TL Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J.
1996;17(suppl D)9- 14Link to Article
TA Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol.
1996;78(suppl 6A)32- 41Link to Article
et al. The influence on coronary events of lipid therapy during treatment with pravastatin: the CARE trial [abstract]. Circulation. 1997;96I- 66
CJ Relationship between LDL-C changes and CHD event reduction with pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS) [abstract]. Circulation. 1997;96I- 107
Not Available, Drug Topics Red Book Update. Montvale, NJ Medical Economics July1998;
TA Preventing CHD in the managed care era: improving the cost-effectiveness of lipid lowering therapy. Am J Managed Care. 1997;3(suppl)S29- S41
et al. Cholesterol-Reduction Intervention Study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med.
1996;156731- 739Link to Article
et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol.
1995;7534- 39Link to Article
Jr Task Force 8: organization of preventive cardiology service. J Am Coll Cardiol.
1996;271039- 1047Link to Article
et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation.
1997;951683- 1685Link to Article